

Here is a list of principal investigators, current research projects,
and funding sources:
C.M. Townsend, Jr., M.D., Studies in Gastrointestinal Endocrinology
(Program Project Grant), NIH
C.M. Townsend, Jr., M.D., Surgical Studies of GI Peptides-Mechanisms
of Action, NIH
Elisabet Borsheim, Ph.D., Amino Acid Alterations in Traumatic
Brain Injury, Moody Endowment
Elisabet Borsheim, Ph.D., Visceral Fat Contribution to Very Low
Density Lipoprotein (VLDL)-triglyceride Synthesis in Women, Center
for Interdisciplinary Research in Women's Health
Ella Englander, Ph.D., Hypoxia-Induced DNA Damage and Repair
in the Rat Brain, NIH
Ella Englander, Ph.D., Neuroprotective Role of Neuroglobin in
the Developing Brain in Perinatal Hypoxia, March of Dimes
Ella Englander, Ph.D., Transgenic Neuroglobin Mouse Model of Smoke
Inhalation Injury, Shriners Hospitals for Children
Ella Englander, Ph.D., Mechanisms of Neurotoxicity of Combustion
Smoke Inhalation to the Brain, NIH
Guillermo A. Gomez, M.D., Comparison of surgery versus endoscopic
closure of a large linear colon perforation, Ethicon Endo-Surgery,
Inc.
George H. Greeley, Jr., Ph.D., Role of Apelin in IBD, Crohn's
& Colitis Foundation of America
George H. Greeley, Jr., Ph.D., Modulation of Oxidative Stress
in the Aging Brain, John Sealy Endowment
George H. Greeley, Jr., Ph.D., Regulation of Ghrelin and Growth
Hormone during Aging, John Sealy Endowment
George H. Greeley, Jr., Ph.D., Regulation of Stomach Ghrelin,
NIH
Kristene K. Gugliuzza, M.D., A One-Year, Multicenter, Partially
Blinded, Double-Dummy Randomized Study to Evaluate the Efficacy
and Safety of FTY720 Combined with Reduced-Dose or Full Dose Neoral
and Corticosteroids Versus Mycophenolate Mofetil (MMF, CellCept)
Combined with Full-Dose, Novartis Pharmaceuticals Corporation
Kristene K. Gugliuzza, M.D., Myfortic and Prograf vs. Neoral Efficacy
and GI Complications, Novartis Pharmaceuticals Corporation
Kristene K. Gugliuzza, M.D., A 12-Month Open-label, Randomized,
Multicenter, Sequential Cohort, Dose Finding Study to Evaluate
the Efficacy, Safety and Tolerability of Oral AEB071 versus Tacrolimus
in combination with myfortic®, Simulect®, and corticosteroids
in de novo adult renal transplant recipients, Novartis Pharmaceuticals
Corporation
Kristene K. Gugliuzza, M.D., A Prospective, Randomized, Multi-Center
Double-Blind Study of Early Corticosteroid Cessation vs. Long
Term Maintenance Corticosteroid Therapy with Prograf® and
CellCept® in Primary Renal Transplant Recipients, Astellas
Pharma US, Inc.
Mark R. Hellmich, Ph.D., Studies of a Novel CCK-B/Gastrin Receptor
Splice Variant, John Sealy Endowment
David N. Herndon, M.D., Shrine Research Core, Shriners Hospitals
for Children
David N. Herndon, M.D., Postdoctoral Training in Trauma and Burns,
NIH
David N. Herndon, M.D., Modulation of the Postburn Hypermetabolic
Response, NIH
David N. Herndon, M.D., Pediatric Burn Injury Rehabilitation Model
System, NIDRR
David N. Herndon, M.D., Assess Anabolic Agents/Exercise in Burned
Children, NIGMS
David N. Herndon, M.D., Inflammation and the Host Response to
Injury, Massachusetts General Hospital
Lois A. Killewich, M.D., Ph.D., Phase 3, Multicenter, Multinational,
Randomized, Partial Double-Blind, Placebo-Controlled Study to
Evaluate the Efficacy And Safety of Alfimeprase In Subjects With
Acute Peripheral Arterial Occlusion, Nuvelo, Inc.
Taylor S. Riall, M.D., Ph.D., Underutilization of Surgical Resection
in Patients with Pancreatic Cancer, Society of University Surgeons
Taylor S. Riall, M.D., Ph.D., Pancreatic cancer in the elderly:
Population-based outcomes following surgical resection, American
Geriatrics Society
Oscar E. Suman, Ph.D., Exercise and Quality of Life in Severely
Burned Children, NIH
Oscar E. Suman, Ph.D., Physiological Adaptation to Exercise in
Burned Children, NIH
Philip G. Thomas, M.D., Phase IV Non-Interventional, Multi-Center,
Open-Label, Prospective, Observational Study of the Safety, Effectiveness
& Tolerability of Immunosuppressant Regimens using Mycophenolic
Acid to Treat de novo Renal Transplant Patients in Routine Clinical
Practice, Novartis Pharmaceuticals Corporation
Xiaojun Zhang, M.D., Special Shared Facilities-Mass Spectrometry
Core, Shriners Hospitals for Children
